Business · Markets · 2 hrs ago
ASX healthcare stocks rose 10% in October, outpacing the broader market
The S&P/ASX 200 healthcare group rose 10% in October, while the broader Australian share index gained 2.6%.
Major companies including ProMedicus, CSL and Cochlear recorded monthly gains, though some remained well below their levels a year earlier.
Neurizon Therapeutics is raising up to $6.3 million through a share placement and a planned share purchase offer.
It will use part of the money to buy back convertible notes, and says it remains funded for a trial of its ALS drug candidate, NUZ-001.
The company expects trial results in the March quarter, although no specific date was given.
Separately, 4D Medical shares fell 25% after the company said increased short selling was a likely reason, while Vitura Health denied liability for a $6.5 million penalty involving an acquired clinic.
ASX 200 healthcare stocks rose 10% in October, outperforming the broader ASX 200, which gained 2.6%.
Pro Medicus shares rose 25%, while CSL and Cochlear each gained 14%.
ResMed shares rose 11% and ended the month with solid quarterly numbers.
The healthcare sector’s October gains followed a 1.8% rise in September, when the broader index fell 4%.
- Who
- ASX 200 healthcare companies and the broader ASX 200.
- What
- Healthcare stocks rose 10% in October, compared with a 2.6% gain for the broader index.
- When
- October; the article was published on 2 November 2026.
- Where
- On the Australian Securities Exchange.
- Why
- Not stated.
This story does not have two clearly opposing sides.
ASX 200 healthcare stocks rose 1.8%, while the broader index fell 4%.
ASX 200 healthcare stocks gained 10%, while the broader index rose 2.6%.
- Healthcare sector gain
- 10% in October
- Broader ASX 200 gain
- 2.6% in October
- Pro Medicus share gain
- 25% in October
- CSL share gain
- 14% in October
- Cochlear share gain
- 14% in October
- ResMed share gain
- 11% in October